Background {#sec1}
==========

Depression may affect as many as half of all individuals with tuberculosis (TB) (Sweetland *et al*., [@ref32]), which presents significant challenges to the management of these comorbid illnesses. Anxiety and depression are frequently co-occurring among patients with TB and are associated with poor adherence to anti-TB medications (Ige and Lasebikan, [@ref15]; Duko *et al*. [@ref12]) and higher mortality (Koyanagi *et al*., [@ref20]). When TB and depression co-occur, there is a greater risk for other comorbidities, patients may suffer more, and associated cost increases (Basu *et al*., [@ref8]). Depression may also pose an increased susceptibility to TB reactivation by compromising immunity or through neglected self-care (Sweetland *et al*., [@ref31]). Thus, depression may be an unrecognized driver of the global TB and multidrug-resistant TB (MDR-TB) epidemics (Sweetland *et al*., [@ref32]; Koyanagi *et al*., [@ref20]).

A number of studies have assessed co-morbidity of depression and anxiety with TB (Amreen and Rizvi, [@ref5]). A research study in Nigeria showed that 41.9% TB patients had depressive symptoms. Likewise, research conducted in India showed that the prevalence of depression among TB outpatients was 49%, and 54% in hospitalized TB patients (Adem *et al*., [@ref1]). Similarly, evidence from cross-sectional studies in several African countries found the prevalence of comorbid depression among TB patients in a range from 10% to 52% (Ambaw *et al*., [@ref2]). Two studies in Nepal have assessed the prevalence of depression among patients with drug-susceptible TB and MDR-TB, respectively. At an urban directly observed treatment short-course (DOTS) center in Kathmandu, of the 150 TB patients included in the sample, 18% had depression (Devkota *et al*., [@ref11]). The frequency of mild depression was 16 (11%), for moderate depression was 6 (4%), for severe depression was 3 (2%) and that for very severe depression was 2 (1%). All cases of depression required medical attention. In a recent sample of 135 patients with MDR-TB in Nepal, the prevalence of depression and anxiety were 22.2% and 15.6%, respectively (Walker *et al*., [@ref34]).

The co-occurrence of depression and TB can negatively impact quality of life, health care costs and self-care, as well as decreased immunity; all of these can affect patients\' adherence to TB treatment and TB outcomes (Duko *et al*., [@ref12]; Kunal *et al*., [@ref22]; Sweetland *et al*., [@ref31]; Ambaw *et al*., [@ref4]). Poor treatment adherence not only increases the risk of negative TB outcomes, but also poses a public health risk given the potential for community transmission and/or development of drug resistance (Ambaw *et al*., [@ref3]; Sweetland *et al*., [@ref31]). Psychosocial concerns such as stigma, isolation, limited social support, helplessness, and other psychological reactions to the disclosing TB diagnosis, as well as medication side effects, all adversely impact treatment adherence (Mounika *et al*., [@ref24]).

Given the limited availability of data on the prevalence of depression among TB patients in Nepal, this study was conducted with the aim of identifying the prevalence of depression among TB patients and the social factors associated with it.

Methods {#sec2}
=======

Study design and population {#sec2-1}
---------------------------

A descriptive cross-sectional study was conducted among TB patients currently under treatment in DOTS centers in different treatment centers of Kathmandu Valley to study the prevalence of depression and associated factors. A total of 27 DOTS centers were selected from the three districts of Kathmandu Valley, including 10 from Kathmandu, 11 from Lalitpur, and 6 from Bhaktapur. Urban centers with higher caseloads were preferentially selected to achieve the desired sample size. Patients meeting the inclusion criteria (new adult patients within 2 months of initiating TB treatment) were recruited from these DOTS centers until the desired sample size was achieved. Medications and treatment protocols were identical across all DOTS sites.

Sampling and inclusion criteria {#sec2-2}
-------------------------------

Given that depression may be highest at baseline (Yen *et al*., [@ref35]; Ambaw *et al*., [@ref3]; Dasa *et al*., [@ref10]) and may be higher in patients with MDR-TB (Vega *et al*., [@ref33]), only new TB patients (never treated before) aged 18 years and above in the first 2 months of DOTS treatment (intensive phase) through the National TB Program were considered for the study. In order to maximize comparability across the sample, individuals being re-treated for TB (possible MDR-TB) or who had received more than 60 days of treatment (continuation phase) were excluded.

The sample size was calculated using the following formula (Naing *et al*., [@ref25]):where *N* = sample size, *Z*^2^ = *Z* statistic for a level of confidence (95%), *P* = prevalence (18%) (Devkota *et al*., [@ref11]), and *d* = precision (5%).

Based on the above mentioned values, the sample size (*N*) was calculated as follows:

Adding 10% non-response rate,

Measurement {#sec2-3}
-----------

The previously validated Nepali Patient Health Questionnaire (PHQ-9) (Kohrt *et al*., [@ref19]) was used to screen for depression (dependent variable). The PHQ-9 was originally developed to be a self-administered screening tool for patients in medical settings based on the PRIME-MD (Kroenke *et al*., [@ref21]), but is often administered via interview in low literacy settings (Kohrt *et al*., [@ref19]). Using a cutoff score of ⩾10, the Nepali PHQ-9 has demonstrated a sensitivity of 0.94 and a specificity of 0.80 (Kohrt *et al*., [@ref19]). Independent variables included sociodemographic characteristics, social stigma, perceived social support, medication adherence, and TB-related side effects. To assess social stigma, patients were asked several questions based on prior studies including if they had disclosed their TB status to family and friends, had direct experiences of stigma or discrimination, felt guilty or shy about their TB status, and/or felt helplessness or loneliness due to their diagnosis. Patients were also asked to rate their perceived social support, whether they had ever forgotten to take their medications (adherence), and if they experienced any TB-related side effects.

Data collection {#sec2-4}
---------------

The health workers of the respective DOTS centers were oriented about the study as well as informed about the use of PHQ-9. Trained research assistants administered the PHQ-9 to assess the frequency and severity of depressive symptoms, followed by a semi-structured interview to obtain socio-demographic characteristics, TB-related information, and other factors.

Ethical approval was obtained from the Department of Psychology and Philosophy, Tri Chandra Multiple Campus, Kathmandu to conduct the study. Verbal informed consent was obtained from the participants prior to the study. The consent form was designed and approved before inclusion of participants in the study. The participants were informed about the purpose of the study, about their voluntary participation in the study and their right to leave the study at any time. Confidentiality was maintained at all levels of the study. The data collected were also kept confidential and used by the researcher for the study purpose only.

Data analysis {#sec2-5}
-------------

The collected data was entered into IBM SPSS Statistics version 20. Given the strong overlap in TB and depressive symptoms, and the fact that the screening scale was previously validated among a non-TB sample, we decided to analyze the PHQ-9 data in two ways including logistic (depression as binary using a cut off score of 10) and linear (depression symptoms as continuous) regressions. The age group and educational level were treated as ordinal variables, whereas other sociodemographic variables were treated categorically, including sex (male = 0, female = 1), marital status, and occupation. For marital status we used 'married' as the default comparison group and created two dummy variables for 'never married' or 'separated/widowed/divorced.' For occupation, we compared 'wage labor' and 'student' to everything else.

Results {#sec3}
=======

Sociodemographic characteristics of respondents {#sec3-1}
-----------------------------------------------

The sociodemographic characteristics of the sample are described in [Table 1](#tab01){ref-type="table"}. The mean age the respondents was 32.69 (range 18--84, [s.d.]{.smallcaps} 14.86). The largest age group was between 18--24 years with 40% of the total respondents. The sex distribution was 55% male and 45% female. Approximately half (53%) were married and 44% had never married. Nearly one third (31.6%) of the respondents were current students. One quarter (26.0%) had completed their higher secondary education, and 20.8% had achieved a bachelor\'s degree or higher. Table 1.Sociodemographic characteristics of respondents (*n*=250)FrequencyPercentAge of respondents18--24 years10140.425--34 years5823.235--44 years4417.645--54 years249.655--64 years72.865 years and above166.4Sex of respondentsMale13855.2Female11244.8Marital status of respondentsNever married11044.0Married13252.8Others (separated, divorced, widow/   widower)83.2Educational status of respondentsIlliterate197.6Informal education124.8Primary level3112.4Lower secondary level3714.8Secondary level3413.6Higher secondary level6526.0Bachelors level3915.6Masters level and above135.2Occupational status of respondentsHousewife3614.4Government service72.8Non-government service218.4Business4016Daily wages labor2911.6Agriculture228.8Student7931.6Not working166.4

Factors associated with TB {#sec3-2}
--------------------------

The sample included new cases of TB in the first phase of treatment (see [Table 2](#tab02){ref-type="table"}). Of the total respondents, almost 50% (*n* = 124) were bacteriologically confirmed new pulmonary TB cases, 44.8% had extrapulmonary TB, and 5.6% were diagnosed by clinical pulmonary assessment. A total of 206 respondents (82.4%) were aware of their human immunodeficiency virus (HIV) status; of these, 94.6% (*n* = 195) were HIV negative and 4.4% (*n* = 11) were HIV positive. Approximately 69% respondents had disclosed their TB status to their family members, friends, and relatives and among those, 87% perceived good social support. Although only 5.6% (*n* = 14) of respondents reported experiences of stigma or discrimination because of TB, 13.2% (*n* = 33) respondents felt guilty or shy, 10.4% (*n* = 26) felt loneliness, and 7.2% (*n* = 18) respondents felt helplessness due to TB. A total of 6.8% of respondents (*n* = 17) self-reported having forgotten to take their TB medications at least one time during treatment so far and about 30% respondents (*n* = 74) had experienced some TB-related side effects at least once. Table 2.TB associated factors (*n*=250)FrequencyPercentTypes of TBNew PBC (pulmonary bacteriologically   confirmed)12449.6New PCD (pulmonary clinically diagnosed)145.6New EP (extra pulmonary)11244.8HIV infectionYes114.4No19578.0Unknown4417.6Known status of TB among family, friends and relativesYes17268.8No7831.2Perceived support from family, friends and relativesYes15087.2No2212.8Feeling of stigma or discrimination due to TBYes145.6No23694.4Feeling of guilty or shy due to TBYes3313.2No21786.8Feeling of loneliness due to TBYes2610.4No22489.6Feeling of helplessness due to TBYes187.2No23292.8Forgotten to take TB medications (at least one time during the course of treatment)Yes176.8No23393.2Experience of side effects from TB medications (at least one time during the course of treatment)Yes7429.6No17670.4

PHQ-9 score and depression {#sec3-3}
--------------------------

Among the respondents, 10.0% (*n* = 25) had scores above the cut off of 10, suggestive of probable depression. Forty-four patients (17.6%) reported that depressive symptoms negatively impacted their daily lives in their work, self-care, care for and/or relationship with others. When asked whether they perceived that people with TB had greater risk for depression, 18.0% (*n* = 45) agreed. Most patients (97.2%) believed that their TB would be cured (see [Table 3](#tab03){ref-type="table"}). Table 3.PHQ score and depression (*n*=250)FrequencyPercentPresence of symptoms of depression (based on PHQ score ⩾10)Yes2510.0No22590.0How often in the past two weeks have the problems affected your work, self-care and your care for family and your relationship with others?Never20682.4Sometimes2911.6Often156Patient\'s perception on TB patients at risk of depressionYes4518.0No20582.0Patient\'s perception on curability of their TBYes24397.2No72.8

Association between PHQ-9 score and socio-demographic and TB-related factors {#sec3-4}
----------------------------------------------------------------------------

Bivariate linear (continuous regression) analysis found that the higher PHQ score was associated with older age (*p* = 0.009), marital status \[never married (*p* = 0.008) and separated/widowed/divorced (*p* = 0.000)\], and occupation \[student (*p* = 0.027)\]. When controlling for other sociodemographic factors through multivariate linear (continuous regression) analysis, age and occupation were no longer significant, and only being separated/widowed/divorced and having lower education were significant risk factors for higher PHQ-9 scores (*p* = 0.000 and *p* = 0.003, respectively). When treating PHQ-9 score as binary variable indicating the presence or absence of probable depression (above and below 10), multivariate logistic (binary regression) analysis found the same pattern of results ([Table 4](#tab04){ref-type="table"}). Additional risk factors for high depressive symptoms were current smoking (*p* = 0.02), current drinking (*p* = 0.001), and having experienced TB-related side effects (*p* = 0.001) ([Table 5](#tab05){ref-type="table"}). Table 4.Relationship of PHQ score and symptoms of depression with socio demographic variablesConstantBivariate linear (continuous) regressionMultivariate linear (continuous) regressionMultivariate logistic (binary) regressionB[s.e.]{.smallcaps}*p* ValueB[s.e.]{.smallcaps}*p* ValueB[s.e.]{.smallcaps}*p* Value------4.8172.9550.1041.6740.1860.000Age group0.5550.210.009[\*](#tfn4_1){ref-type="table-fn"}−0.0260.2780.9270.0160.0170.362Sex0.4280.6260.4950.0150.6270.9820.0140.0390.726Marital statusNever married−1.6530.6190.008[\*](#tfn4_1){ref-type="table-fn"}−0.6470.880.4630.0720.0550.194Separated/widowed/divorced8.2961.690.000[\*](#tfn4_1){ref-type="table-fn"}6.8801.7290.000[\*](#tfn4_1){ref-type="table-fn"}−0.3570.1090.001[\*](#tfn4_1){ref-type="table-fn"}Education−0.3230.1680.055−0.5680.1920.003[\*](#tfn4_1){ref-type="table-fn"}0.0290.0120.016[\*](#tfn4_1){ref-type="table-fn"}OccupationStudent1.4740.6630.027[\*](#tfn4_1){ref-type="table-fn"}−0.3190.9520.7380.0430.060.471Daily wage laborers−0.7230.9720.4580.4621.0130.649−0.0190.0640.761[^1] Table 5.Relationship of PHQ score with TB related factorsTB related factors*N*%B[s.e.]{.smallcaps}*p* ValueType of TB (*n* = 250)Extra pulmonary TB11244.8%0.3310.6260.597Pulmonary TB13855.2%HIV status (*n* = 206)Positive115.3%1.8971.4680.198Negative19594.7%Experience of side effects from TB medications (*n* = 250)Yes7429.6%2.180.6680.001[\*](#tfn5_1){ref-type="table-fn"}No17670.4%Forgotten to take TB medications (*n* = 250)Yes176.8%0.7991.2360.519No23393.2%Disclosure of TB status to family and friends (*n* = 250)Yes17268.8%−0.9910.6260.597No7831.2%Current smoking status (*n* = 250)Yes124.8%1.3790.5910.02\*No23895.2%Current alcohol use status (*n* = 250)Yes218.4%1.7330.5160.001\*No22991.6%[^2]

Discussion {#sec4}
==========

The prevalence of depression in our study was lower than findings from two other studies conducted in Nepal. In the first study among an urban sample patient with TB or MDR-TB, 18% suffered from some levels of depression requiring medical attention (Devkota *et al*., [@ref11]). In a more recent study among only MDR-TB patients, the prevalence of depression was estimated as 22.2%. It is unclear why the prevalence of depression was significantly lower in our sample (10%); one reason could be that we excluded MDR-TB patients, who have a greater risk for depression (Vega *et al*., [@ref33]), or because we used a different depression screening tool.

In fact, estimating depression prevalence in TB patients using screening tools, in general, is inherently problematic. Given the strong overlap of symptoms between TB and depression, particularly physical symptoms (e.g. changes in appetite, sleep, or energy level), it is not clear if it is even valid to use the same cut-off score used in validation studies among non-TB patients (Castro Silva *et al*., [@ref9]). Individuals with high scores on self-report measures of depressive symptoms and meet interviewer-rated psychiatric diagnostic criteria (true positives) differ in important ways from individuals who obtain similarly high scores on self-report measures of depressive symptoms but do not meet interviewer-rated criteria for a diagnosis of depression (false positives) (Gotlib *et al*., [@ref13]). That said, the PHQ-9 is one of the most widely used globally to screen for depression among TB patients. Compared to other studies using the PHQ-9 among TB patients, the prevalence of depression in our sample was lower than samples from Cameroon (25%) India (42%), Ethiopia (54%), Pakistan (56%), and Brazil (62%) (Mandaknalli and Giriraj, [@ref23]; Amreen and Rizvi, [@ref5]; Kehbila *et al*., [@ref17]; Ambaw *et al*., [@ref3]; Castro Silva *et al*., [@ref9]) but higher than one study in Nigeria (6.2%) (Issa *et al*., [@ref16]). Other global studies using Hospital Depression & Anxiety Scale found similarly high prevalence estimates for depression including 47% (India), 46% (Pakistan), and 43% (Ethiopia) (Husain *et al*., [@ref14]; Duko *et al*., [@ref12]; Kunal *et al*., [@ref22]). When examining depression and anxiety together, two studies found a prevalence of 72% (Pakistan) and 80% (India) (Mounika *et al*., [@ref24]; Siddiqua and Aisha, [@ref27]). In Nigerian study using the Hamilton Depression Rating Scale, the prevalence of moderate depression was 32% (Ige and Lasebikan, [@ref16]).

In terms of sociodemographic correlates, we found that being separated/widowed/divorced and/or lower educational attainment were the only significant risk factors for depression in our sample. These findings differ from a cross-sectional, community-based dataset from 48 low and middle-income countries, in which the prevalence of depressive episodes among those with TB based on the Composite International Diagnostic Interview was 23.7%, and was significantly associated with older age, female sex, lower levels of wealth, smoking, and diabetes (Koyanagi *et al*., [@ref20]). That said, low education and marital disruption are among the most common social correlates with depression across cultures based on the World Mental Health Survey (Kessler and Bromet, [@ref18]).

TB-related stigma and discrimination are still highly prevalent worldwide, and are associated with greater risk for depression (Sweetland *et al*., [@ref31]). In our sample, 31% patient did not disclose their TB status among family, and many endorsed experiencing feelings of guilt, loneliness, and helplessness due to TB. Several studies have explored TB-related stigma in Nepal. One study among 60 TB patients found that 63.3% (*n* = 38) of the subjects had experienced stigma (Aryal *et al*., [@ref6]), while another study among 89 patients revealed 64% of people were stigmatized due to TB (Priyanka and Dahal, [@ref26]). A qualitative study in Nepal that sought to identify the causes of TB-related stigma and self-discrimination found patient\'s fear of transmission of disease and fear of gossip as the two main contributors (Baral *et al*., [@ref7]). Causes of discrimination by the community included fear of perceived risk of infection; perceived links between TB and poverty and low caste; perceived links between TB and disreputable behavior; and perceptions that TB was a divine punishment. Of note, some patients felt they were discriminated against by health workers (Baral *et al*., [@ref6]).

Conclusions {#sec5}
===========

This study revealed that depression is a significant challenge for TB patients in Nepal, requiring attention by the NTP and TB providers. The WHO End TB strategy explicitly calls for integrated patient-centered care, including the treatment of mental disorders, in order to achieve TB elimination (Stop TB Partnership, [@ref28]), and the WHO recently called for a TB and Mental Health collaborative framework to meet these needs (Sweetland *et al*., [@ref30]). Furthermore, many NTP directors globally have expressed openness to integrating counseling and brief psychological interventions that have demonstrated effectiveness (Sweetland *et al*., [@ref29]). Routine screening for depressive symptoms among TB patients, followed by a timely confirmatory diagnosis so such patients can receive treatment in order to improve the likelihood of positive TB outcomes (Sweetland *et al*., [@ref31]). Operational research may guide programs how to best implement this across settings.
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